Diplomat Pharmacy (DPLO) Misses Q3 EPS by 3c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St eyes best day in a month as Anthropic's IPO filing propels AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazilās Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Britain will not join Canada-led defence bank initiativeĀ
- CAE agrees to sell Flightscape unit to SITA for $500 million
Avondale Partners Downgrades Diplomat Pharmacy (DPLO) to Market Perform
November 3, 2016 7:42 AM EDTAvondale Partners downgraded Diplomat Pharmacy (NYSE: DPLO) from Market Outperform to Market Perform.
For an analyst ratings summary and ratings history on Diplomat Pharmacy click here. For more ratings news on Diplomat Pharmacy click here.
Shares of Diplomat Pharmacy closed at $22.38 yesterday.
... MoreLeerink Partners Downgrades Diplomat Pharmacy (DPLO) to Market Perform
November 3, 2016 6:59 AM EDTLeerink Partners downgraded Diplomat Pharmacy (NYSE: DPLO) from Outperform to Market Perform with a price target of $18.00 (from $35.00).
Analyst David Larsen commented, "Yesterday afternoon DPLO reduced its outlook for 2016 and provided a preliminary outlook for 2017 that was well below expectations. As a... More



